Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of oral fexinidazole dosing regimens in adults with chronic indeterminate Chagas disease
2016-004905-15Phase 2Completed
- Sponsor
- Drugs for Neglected Diseases initiative
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Fexinidazole in American trypanosomiasis (CD), sponsored by Drugs for Neglected Diseases initiative. Primary endpoint: Sustained parasitological response by qualitative PCR. Started May 2017; status: completed.
02
Drugs
Fexinidazole
03
Conditions
American trypanosomiasis (CD)
Beyond the preview
Go deeper on 2016-004905-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004905-15.